RTP Mobile Logo

Friday, May 18, 2018, Washington, DC, 12:15 PM – 1:45 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A CNE Symposia Series Held During the 43rd Annual ONS Congress

PART 6 — Breast Cancer

Event Details

Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
11:45 AM – 12:15 PM
Registration and Lunch Buffet

12:15 PM – 1:45 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Lisa A Carey, MD
Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
Chief, Division of Hematology and Oncology
North Carolina Cancer Hospital
Associate Director for Clinical Research
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Lauren Czapla, MSN, WHNP-BC, AOCNP
Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program, Division of Hematology/Oncology
University of California, Los Angeles
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California

Madelaine C Kuiper, NP
Nurse Practitioner
University of California, Los Angeles
Santa Monica, California

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by Genentech BioOncology, Lilly, Merck and Novartis during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Module 1: HER2-Positive Breast Cancer (BC)


  • Indications for neoadjuvant systemic therapy and selection of optimal approach
  • Importance of age, nodal status and planned surgical approach in the use of neoadjuvant systemic therapy for patients with HER2-positive BC
  • Results from the Phase III APHINITY trial evaluating the addition of pertuzumab to chemotherapy and trastuzumab as adjuvant therapy for HER2-positive primary BC
  • Monitoring patients for cardiac side effects during adjuvant anti-HER2 therapy; care considerations for patients receiving anthracycline versus nonanthracycline regimens
  • FDA approval of neratinib as extended adjuvant therapy; patient selection and clinical factors guiding its use in clinical practice
  • Common side effects observed with neratinib; potential strategies to mitigate associated gastrointestinal toxicity
  • Clinical factors influencing the sequencing of anti-HER2 agents in the metastatic setting; integration of T-DM1 into the treatment algorithm
  • Efficacy and safety of neratinib/capecitabine for patients with HER2-positive BC and brain metastases; other available agents and strategies with CNS activity
  • Ongoing trials evaluating novel agents and strategies for patients with HER2-positive BC

Module 2: ER-Positive, HER2-Negative BC


  • Optimizing first-line systemic therapy for patients with metastatic ER-positive BC; impact of prior hormonal therapy, symptomatology, performance status and disease-free interval
  • Comparative activity, side effects and CNS penetration of available CDK4/6 inhibitors
  • Recent FDA approvals of ribociclib and abemaciclib and integration into clinical algorithms for ER-positive metastatic BC
  • Available data with and current clinical role of CDK4/6 inhibitors for premenopausal patients
  • Incidence, monitoring and treatment of commonly occurring toxicities in patients receiving CDK4/6 inhibitors
  • Incorporating everolimus into the treatment algorithm for patients with ER-positive metastatic BC
  • Prevention and management of everolimus-associated mucositis/stomatitis

Module 3: Triple-Negative BC


  • Indications for BRCA mutation testing in patients with BC; implications of a BRCA1/2 germline mutation for prognosis and current therapeutic selection
  • Biologic rationale for the evaluation of PARP inhibitors in patients with BRCA1/2 germline mutations
  • Recent FDA approval of olaparib and Phase III results from the OlympiAD trial documenting a progression-free survival advantage with olaparib versus chemotherapy for germline BRCA mutation-positive, HER2-negative metastatic BC
  • Ongoing clinical trials of PARP inhibitors (niraparib, veliparib, et cetera) in patients with early and advanced BC
  • Available data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic agents

CE Information

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with early and advanced BC.
  • Describe the influence of tumor phenotypes and/or molecular profiling assays in tailoring systemic treatment decisions for patients with early and advanced BC.
  • Discuss the benefits and risks associated with existing and recently approved evidence-based therapies for BC, including endocrine agents, chemotherapy regimens and biologic treatments.
  • Develop a plan to manage the side effects associated with commonly employed systemic therapies to support quality of life and continuation of treatment.
  • Recall ongoing trials of other investigational approaches and agents in BC, and refer patients and obtain consent for study participation.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with BC to optimize clinical and quality-of-life outcomes.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2018/ILNA

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP staff and external reviewers — The scientific staff, planners and managers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Genentech BioOncology, Lilly, Merck and Novartis.


Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room: 
Independence A-E (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and provides direct access to the Walter E Washington Convention Center via an underground concourse.



Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 6 — Breast Cancer. Onsite registration will be open starting at 11:45 AM (ET) on Friday, May 18th.

If you are interested in standing by for seating (day of the program), please visit our registration desk located outside Independence A-E, Ballroom (Meeting Level 4) at the Marriott Marquis Washington, DC (901 Massachusetts Ave NW, Washington, DC 20001). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.